The ALG 265 blue pill is identified as an immediate‑release tablet of Oxycodone 30 mg manufactured by Alvogen, Inc., and it is a U.S. Schedule II opioid analgesic used for severe pain when non‑opioid options are inadequate. It is a blue, round, biconvex tablet about 6 mm in diameter, debossed “ALG 265” on one side with a score line on the other, and corresponds to NDC 47781‑0265.
What is ALG 265 Blue Pill?
ALG 265 is the imprint on a blue, round immediate‑release oxycodone hydrochloride 30 mg tablet supplied by Alvogen, Inc. under an Abbreviated New Drug Application.
Oxycodone is an opioid (narcotic analgesic) indicated for the management of pain severe enough to require an opioid and for which alternative treatments are inadequate. In the U.S., oxycodone products like ALG 265 are classified as Schedule II due to high abuse potential and risk of dependence
How to identify
The ALG 265 tablet is blue, round, approximately 6.00 mm in size, and debossed “ALG 265” on one face with a functional score line on the reverse.
Pill identifiers list this imprint as oxycodone 30 mg, prescription‑only, with images matching the described color and shape for verification. Additional identifiers include NDC 47781‑0265 and image references describing the same blue round ALG 265 tablet for 30 mg oxycodone.
Manufacturer and formulation
Alvogen, Inc. manufactures the ALG‑series oxycodone immediate‑release tablets in multiple strengths distinguished by color and imprint: 5 mg (white, ALG 263), 15 mg (green, ALG 264), and 30 mg (blue, ALG 265).
The ALG 265 tablet is the 30 mg immediate‑release strength, not an extended‑release formulation, and is supplied under Alvogen’s ANDA labeling. The product is distributed as prescription‑only and controlled under DEA Schedule CII.
Ingredients
The active ingredient is oxycodone hydrochloride 30 mg per tablet. Commonly listed inactive ingredients include silicon dioxide, microcrystalline cellulose, corn starch, stearic acid, FD&C Blue No. 2, and D&C Yellow No. 10, noting excipients may vary by lot. All excipients serve tablet manufacturing, color, and stability purposes and do not contribute to analgesic effect
Approved uses
Per the official labeling, oxycodone immediate‑release tablets are indicated for the management of severe pain where alternative treatments fail or are not tolerated, reflecting the elevated risk profile of opioids.
Consumer‑facing drug monographs also describe oxycodone as a strong opioid reserved for severe pain, such as certain cases of chronic pain or post‑procedure scenarios, under clinician oversight. ALG 265 specifically corresponds to the 30 mg strength within that indication scope.
Safety and boxed warnings
Oxycodone carries boxed and major warnings including addiction, abuse, and misuse risks; life‑threatening respiratory depression; and heightened dangers when combined with benzodiazepines or other CNS depressants, including alcohol.
The label emphasizes careful patient selection, close monitoring during initiation and titration, and minimizing concomitant sedatives due to the risk of profound sedation, respiratory depression, coma, or death.
Additional precautions include risks for adrenal insufficiency, severe hypotension, and special caution in elderly or pulmonary‑compromised patients.
Contraindications
The ALG 265 (oxycodone 30 mg) tablet is contraindicated in significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment, known or suspected gastrointestinal obstruction (including paralytic ileus), and known hypersensitivity to oxycodone.
Careful assessment is required in patients with increased intracranial pressure, head injury, or impaired consciousness due to heightened risk of CO₂ retention and respiratory depression. These contraindications reflect the opioid class risks and the potency of the 30 mg immediate‑release strength.
Common side effects
Frequent adverse effects include constipation, nausea, vomiting, stomach pain, headache, dizziness, drowsiness, and pruritus, consistent with opioid pharmacology and consumer monographs.
Serious adverse effects include respiratory depression, severe hypotension, and signs of overdose such as extreme sleepiness, slowed breathing, or cyanosis that require emergency care.
Patients may also experience opioid‑induced hyperalgesia, necessitating clinical evaluation and potential dose adjustment or rotation per labeling.
Interactions to avoid
Concomitant use with benzodiazepines, other opioids, sedative‑hypnotics, or alcohol markedly increases the risk of profound sedation, respiratory depression, and death, so such combinations should be avoided or undertaken only with strict medical oversight.
The label advises careful dose adjustments and monitoring when CYP‑modulating drugs or CNS depressants are co‑administered due to altered oxycodone effects and additive sedation. Consumer resources also warn against alcohol and sedatives while on oxycodone to reduce respiratory and CNS risks.
Counterfeits and safety checks
Law enforcement and medical examiner alerts have documented counterfeit “oxycodone” tablets mimicking authentic markings—including seizures of pills stamped “ALG 265” that actually contained dangerous non‑oxycodone synthetics like U‑47700 and furanyl fentanyl.
The DEA has repeatedly warned about a surge of counterfeit blue “oxycodone” tablets (often seen as various “30” imprints) laced with fentanyl, underscoring the need to obtain medications only from licensed pharmacies.
Always verify legitimate characteristics—imprint “ALG 265,” blue round shape, ~6 mm size, scored reverse—and confirm with pharmacy or pill‑identifier tools if authenticity is in question.
FAQs
- Is ALG 265 the same as “M30”? No—both refer to 30 mg immediate‑release oxycodone tablets, but “ALG 265” is Alvogen’s imprint while “M30” is a different manufacturer’s mark commonly associated with oxycodone; note that counterfeit “M30” pills are prevalent in DEA alerts.
- Can the ALG 265 tablet be split? The tablet has a score line, but splitting should only follow prescriber guidance to maintain safe dosing and minimize misuse risks inherent to potent immediate‑release opioids.
- Is ALG 265 a controlled substance? Yes, oxycodone is a U.S. Schedule II controlled substance due to high abuse potential and dependence risk.
Quick verification checklist
- Imprint: ALG 265; Color/Shape: blue, round, biconvex; Size: ~6 mm; Reverse: scored; Strength: 30 mg immediate‑release oxycodone; Manufacturer: Alvogen (NDC 47781‑0265).
- Uses: severe pain requiring an opioid when alternatives are inadequate; Class: opioid analgesic; Schedule: CII.
- Counterfeit caution: avoid non‑pharmacy sources; counterfeit ALG‑marked tablets have been seized with illicit fentanyl‑like substances.
Related strengths in the ALG series
- ALG 263: 5 mg oxycodone, white, round, immediate‑release.
- ALG 264: 15 mg oxycodone, green, round, immediate‑release.
- ALG 265: 30 mg oxycodone, blue, round, immediate‑release.
Bottom line
ALG 265 blue is authentic Alvogen immediate‑release oxycodone 30 mg, a potent Schedule II opioid intended only for severe pain under medical supervision, with distinct blue round scored appearance and ALG 265 imprint for identification. Given the widespread circulation of counterfeit blue “30” tablets, authentic supply verification and adherence to labeled warnings are critical to reduce overdose risk and harm.